Breakthroughs in the treatment and prevention of Clostridium difficile infection.
about
The microbiota and immune response during Clostridium difficile infection.Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291.Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings.Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model.Nonantimicrobial drug targets for Clostridium difficile infections.Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination.Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile.Use of broadly neutralizing antibodies for HIV-1 prevention.Nutrition and the gut microbiome in the elderly.Old and new models for studying host-microbe interactions in health and disease: C. difficile as an example.A Review of the Safety and Efficacy of Vaccines as Prophylaxis for Clostridium difficile Infections.Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?Clostridium difficile Infection and the Role of Adaptive Immunity in the Microbiome.Genome Sequence of a Toxin-Positive Clostridium difficile Strain Isolated from Murine Feces.Strategies for Optimizing the Diagnostic Predictive Value of Clostridium difficile Molecular Diagnostics.Toxin-positive Clostridium difficile latently infect mouse colonies and protect against highly pathogenic C. difficile.The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.Inactivation of the dnaK gene in Clostridium difficile 630 Δerm yields a temperature-sensitive phenotype and increases biofilm-forming ability.Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile.The role of toxins in Clostridium difficile infection.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model.Bezlotoxumab.Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection.Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections.A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile.Protective Effects of Bifidobacterial Strains Against Toxigenic Clostridium difficile.
P2860
Q30276756-34534700-DFDE-4B19-810E-24AF8E6F2BF2Q30834661-AD185DCB-1524-42CC-B850-28107E77D521Q36013358-0B638131-8DCC-47EC-9B12-F3C941384981Q36391688-BE80D315-ADED-4912-B8EA-FFD98F1B70EBQ37119942-246E921A-B1E7-4A9F-86DB-BF9BEF5D1D83Q37239550-1F90E664-1333-4D06-830E-9A20CCD3EDDFQ38376098-C2A7FEEA-6D59-4539-850F-9C2FDDEE5BA7Q38633032-567E44E2-170C-45B5-A6FC-514999AA70C0Q38649348-09E17B48-19FA-4AA1-B911-6C8FE288B6CDQ38668483-7578D5A7-6B14-4771-84CB-70CFBEBE0F0DQ38707993-9FC25D69-D374-4C6E-ACB1-0624E001962EQ38717600-9048B664-F0EC-4408-856C-36CE1D0BDEA6Q38764543-B5AFF2E4-2CB3-4094-AD3C-34D9E4649484Q38997378-6EF04DF5-60AD-4193-AD70-1F508B37CEACQ39209496-91E759B3-508C-46B8-9427-12F8F49AE9C9Q40068051-F46E743C-6FD6-4BEB-BC56-366FDC7E8A07Q40110130-64924DD1-C5EC-489B-8704-B8F144E9F8BFQ40155716-5678EC0F-96FC-45C2-8055-A5582093B06CQ40261448-885F8519-91D6-4D88-AC6B-A772EA4210ADQ40302301-9B1F0625-E394-4D59-85BD-F655AD023561Q40324807-9A77DE31-938A-48FF-9EA3-1110908D085DQ40499019-8E126123-6557-4802-A7C3-2B68DEBE0C65Q47117559-A36E46AA-61F3-46A2-B217-C2FE94D561BBQ47164620-5493F9D5-A58C-4F71-AD87-4195BE1BE4A6Q47734724-31603125-DA12-48D7-872C-69C803C8269EQ49201152-469478C5-0AFD-447D-A503-6FBCF6E28686Q50041908-D9F6B25F-4027-4478-A9BD-C6B45D803CEBQ53762105-208AF136-D65E-4FED-A0C7-C743CC010823Q54245367-407DD0A8-FC41-495F-B46E-CEE11FA3FA94Q54267984-2BF50AE9-2ABF-496D-8A09-10B889DF8E0BQ55311464-6A8C0B4A-3FA9-4695-B787-5A3EE9767E50Q55333418-48195916-EFAC-4BE4-ACA1-F5E68B7EE22FQ55422865-8431A67C-5ADC-428D-A874-A72B78085F31
P2860
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@ast
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@en
type
label
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@ast
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@en
prefLabel
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@ast
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@en
P2860
P1476
Breakthroughs in the treatment and prevention of Clostridium difficile infection.
@en
P2093
Larry K Kociolek
P2860
P2888
P304
P356
10.1038/NRGASTRO.2015.220
P407
P577
2016-02-10T00:00:00Z